Equities research analysts forecast that Cellectis SA (NASDAQ:CLLS) will announce sales of $3.45 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cellectis’ earnings, with the highest sales estimate coming in at $8.00 million and the lowest estimate coming in at $500,000.00. Cellectis reported sales of $2.19 million during the same quarter last year, which would indicate a positive year over year growth rate of 57.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.

On average, analysts expect that Cellectis will report full-year sales of $14.27 million for the current fiscal year, with estimates ranging from $10.14 million to $22.40 million. For the next financial year, analysts anticipate that the firm will post sales of $48.30 million, with estimates ranging from $15.00 million to $82.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Cellectis.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $3.45 million.

A number of analysts recently issued reports on CLLS shares. Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the stock a “hold” rating in a report on Monday, August 12th. Citigroup reiterated a “neutral” rating and issued a $22.00 target price on shares of Cellectis in a research note on Friday, May 24th. BTIG Research initiated coverage on shares of Cellectis in a research note on Friday, August 9th. They issued a “buy” rating and a $37.00 target price for the company. Zacks Investment Research downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $31.67.

Several hedge funds have recently added to or reduced their stakes in the company. OneAscent Financial Services LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $257,000. D. E. Shaw & Co. Inc. bought a new position in shares of Cellectis in the second quarter valued at approximately $502,000. Cubist Systematic Strategies LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $103,000. Point72 Asset Management L.P. boosted its position in shares of Cellectis by 66.9% in the second quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after acquiring an additional 57,100 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Cellectis in the second quarter valued at approximately $772,000. Institutional investors own 31.95% of the company’s stock.

NASDAQ CLLS traded up $0.47 during trading hours on Friday, reaching $12.89. 4,692 shares of the company were exchanged, compared to its average volume of 112,600. Cellectis has a 1 year low of $11.70 and a 1 year high of $29.97. The business’s 50 day simple moving average is $14.67 and its 200-day simple moving average is $17.08. The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $516.67 million, a P/E ratio of -6.68 and a beta of 1.72.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Featured Article: Hold Rating

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.